China Medicine Developers Conference
"722"Restarting China's pharmaceutical R&D, accelerating review and approval processes, medical insurance reforms, policy incentives, capital support, the pressure of centralized procurement, and joiningICHUnder the favorable situation of aligning with international standards, China's pharmaceutical research and development has accelerated.CDEaccepted1New drug-likeINDNumber of Varieties2017year208The number has increased to2021year953one,4An increase of3.6After that, it enters a stable state. Over the years, by introducing international advanced scientific research achievements, China has rapidly enhanced its pharmaceutical R&D capabilities. However, now, China's pharmaceutical research is shifting from mere input to a combination of input and output. Pharmaceutical products independently developed by Chinese enterprises are frequently going global, recognized by international leading pharmaceutical companies and purchased at high prices. Currently, China's pharmaceutical R&D has entered a new stage. With the increasing market launch of innovative drugs, the commercialization and internationalization of these drugs have become focal points. Only by quickly recovering research costs and achieving profitability can a virtuous cycle of R&D be realized.
In order to further promote the R & D technology level of domestic pharmaceutical enterprises, Pharmaceutical Knowledge2024year1monthNovember - DecemberThe China Medicine Developers Conference is held in Chengdu on the day2024The 'Western China Innovation Summit' includes a main forum and nine sub-forums held concurrently, focusing on new drug research and development and process studies of protein drugs, antibody drugs, and small molecule chemical drugs.
Frost & SullivanFrost & SullivanChen Zhenrong, Consulting Director of the Life Sciences Business Unit of Frost & Sullivan in Greater China, was invited to attend the conference and participate in the development sub-forum of conjugated drugs. He also shared his views on “ADCKeynote speech on "The Global Market Structure and Trends of Pharmaceuticals".
Chen Zhenrong briefly introduced the current global and Chinese situationADCOverview of drug research and development. From the currently approved onesADCIn terms of drug status, as of now, globally15modelADCThe drug has been approved for marketing, starting from2019Since the beginning of this year, with outstanding clinical manifestations,ADCThe drug has seen a peak in intensive approvals and launches. At the same time, globally, there are currently more than300anADCCandidate drugs have entered or completed clinical trials. Although most drugs are still in the early research and development stages, globally,ADCDrugs have demonstrated a rich diversity, covering multiple classical and emerging targets.
In recent years, ChinaADCThe number of clinical trials for drugs stands out particularly in the global proportion. In terms of target distribution, China's overall trend is highly consistent with that of the world. Domestic clinical research is ongoingADCAmong the companies with a large number of new drugs, Hengrui Medicine relies on itsHER2andTrop-2has attracted much attention due to rapid progress at the target site. Meanwhile, companies such as Duoxi Biotech and Bio-Thera have alsoADCThe field has made remarkable progress. In terms of specific indications, all of China's currentADCClinical trials are concentrated in the field of oncology treatment.
Chen Zhenrong pointed out that since2020starting from yearADCInvestments in the sector have begun to enter a stage of explosive growth. Especially in China.ADCThe primary market financing in the sector has always maintained a high enthusiasm. Even in a more severe market environment, there is still capital willing to invest in outstandingADCDrug R&D enterprise support. In addition, globallyADCThe authorization and licensing transactions in the field are also showing an active trend. Judging from the data of the past few years,ADCThe number of events for domain authorization licensing transactions since2021It has been increasing continuously since year
"Enter2023year,ADCThe development of the field shows new trends, such as target innovation becoming mainstream, combined immunotherapy, and the continuous expansion of multinational enterprise layouts.ADCMedications are known for their precise targeting. It is believed that with the joint efforts of pharmaceutical companies, the futureADCDrugs can not only be further developed in the field of tumor treatment but also make breakthroughs in other treatment areas." said Chen Zhenrong.
Finally, Chen Zhenrong mentioned that Frost & Sullivan is preparing to write the 'Blue Book on the Current Situation and Development Trends of the Conjugated Drug Industry', aiming to provide an overview of the conjugated drug field (includingADC,RDC,PDC,SMDCConduct in-depth analysis, comprehensively elaborate on its structure, mechanism of action, marketed drugs, research pipelines, market scale, capital enthusiasm, etc., from multiple dimensions. Track the development context of the industry and technology, explore the huge potential for industry development, and analyze the driving factors behind market development. Frost & Sullivan's Life Sciences Practice is now inviting partnering pharmaceutical companies to participate in the Blue Book Jointly explore the development direction and prospects of conjugated drug fields.
👉Cooperation Invitation | Frost & Sullivan to Release 'Blue Book on the Current Situation and Development Trends of the Conjugated Drug Industry'
More exciting moments from the event arena
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life science industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.
